(19)
(11)EP 3 623 470 A3

(12)EUROPEAN PATENT APPLICATION

(88)Date of publication A3:
22.07.2020 Bulletin 2020/30

(43)Date of publication A2:
18.03.2020 Bulletin 2020/12

(21)Application number: 19191719.4

(22)Date of filing:  28.07.2009
(51)International Patent Classification (IPC): 
C12N 9/64(2006.01)
(84)Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

(30)Priority: 28.07.2008 EP 08013561

(62)Application number of the earlier application in accordance with Art. 76 EPC:
17164245.7 / 3241899
14165396.4 / 2767587
09777493.9 / 2318526

(71)Applicant: DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH
60528 Frankfurt am Main (DE)

(72)Inventors:
  • Seifried, Erhard
    61462 Königstein (DE)
  • Schüttrumpf, Jörg
    60596 Frankfurt am Main (DE)

(74)Representative: Grahn, Sibylla Maria 
Boehmert & Boehmert Anwaltspartnerschaft mbB Pettenkoferstrasse 22
80336 München
80336 München (DE)

  


(54)FACTOR IX VARIANTS WITH CLOTTING ACTIVITY IN ABSENCE OF THEIR COFACTOR AND THEIR USE FOR TREATING BLEEDING DISORDERS


(57) The present invention relates to variants of a vitamin K-dependent serine protease of the coagulation cascade, preferably variants of factor IX (F.IX), wherein the variant is characterized in that it has clotting activity in absence of its cofactor. The present invention furthermore relates to the use of these variants for the treatment and/or prophylaxis of bleeding disorders, in particular hemophilia A and/or hemophilia B or hemophilia caused or complicated by inhibitory antibodies to F.VIII. The present invention also relates to further variants of factor IX (F.IX) which have desired properties and can, thus be tailored for respective specific therapeutic applications.





Search report

































Search report